Monoclonal Gammopathy of Undetermined Significance (MGUS). Present in ~5% of all people age 50+ Therefore something all clinicians should know about. Brief summary. #medtwitter ESH (Haematology) 1/

Important article by Matthew Matasar, MD . Highlighting the need to reevaluate the system and realign its purpose!

Mansi Shah discussed the impact of the MagnetisMM-1 and MagnetisMM-3 trials of #elranatamab in patients with relapsed/refractory #multiplemyeloma. #mmsm #RRMM | Rutgers Cancer Institute targetedonc.com/view/elranatam…

I work with some amazing women at Rutgers Cancer Institute !

My millennial heart is exploding. #SuperBowlLVIII #UsherBowl

FDA Approves Bi-weekly Teclistamab Dosing for Relapsed/Refractory Multiple Myeloma onclive.com/view/fda-appro… via @onclive Reduced dose of 1.5 mg/kg every 2 weeks in patients who achieve & maintain remission (CR) for at least 6 months #mmsm International Myeloma Foundation Multiple Myeloma RF @HealthtreeMM

Check out Mansi Shah of Rutgers Cancer Institute and RWJBarnabas Health as she breaks down findings from the PERSEUS trial for patients with newly diagnosed #MultipleMyeloma, recently published in HemOnc Today: bit.ly/4aZXaDJ #MMSM

If daratumumab was a band, I would be a fangirl. Using it upfront during induction as part of a quad shows deep, durable responses. We also use modified DVRd Rutgers Cancer Institute using weekly bortezomib with good tolerability. #PERSEUS #MMSM RWJBarnabas

Very comprehensive and helpful thread about Citta-cel.

Happy to share that Rutgers Cancer Institute has received FACT reaccreditation! It's the result of hard work by the whole team, and reflects the clinical excellence of our BMT and IEC programs - kudos to our BMT chief Dr. Ira Braunschweig (not on Twitter!) and the whole program.

What an earth-quaking announcement! 3rd line BCMA CAR-T Abecma. Looking forward to the Carvykti announcement. I’m shook. #mmsm #cart #earthquake

Totally eclipsed the shake up from earlier today! Amazing news for myeloma all around! #CARVYKTI ® (ciltacabtagene autoleucel) Becomes the First and Only BCMA-Targeted CAR-T Cell Therapy Approved by the FDA for Second-Line Treatment of #MultipleMyeloma businesswire.com/news/home/2024…

Myeloma Paper of the Day, June 17th, suggested by Robert Z. Orlowski Joshua Richter, MD, FACP Dr. Jeffrey Zonder Mansi Shah Suzanne Lentzsch, MD, PhD Swathi Namburi Yariv Houvras Madhav Dhodapkar oncodaily.com/86696.html #Cancer #MyelomaPaperOfTheDay #OncoDaily #Oncology #Myeloma

Just out: My 2024 Update on diagnosis, risk stratification, and treatment of myeloma. #AJH Mayo Clinic Comprehensive Cancer Center 10 Tables; Algorithms Includes current data including trials published this month! #ASCO24 onlinelibrary.wiley.com/doi/10.1002/aj…

🙌 Pleased to publish this review on management of older patients w/ #HodgkinLymphoma w/ Rutgers Cancer Institute RWJBarnabas Heme-Onc chief fellow Marshall McKenna, faculty Yun Kyoung Ryu & colleague Weill Cornell Medicine Sarah Rutherford. Good progress, but more work to do! sciencedirect.com/science/articl…

Want to learn more about how bispecific antibodies work and help treat #MultipleMyeloma? Read this Q&A with CURE® and Mansi Shah of Rutgers Cancer Institute to learn more. #MMSM #BloodCancer curetoday.com/view/how-bispe…

Important to determine risk factors for infections when using bispecific antibodies for myeloma. glad to be part of this collaborative effort! #myeloma #mmsm Rutgers Cancer Institute

It takes >3-4 weeks of steroids (@ any dose >5 mg pred/d) to pose risk of adrenal insufficiency – Hence, Endocrine Society Guideline says short-term glucocorticoid therapy of <3-4 wks, irrespective of dose, DOES NOT require GC tapering buff.ly/4gggMq6

I always think of patients as bortezomib eligible vs. ineligible. Great commentary by this group.